[go: up one dir, main page]

AR067132A1 - Derivados de piperidina 3,5-sustituidos como inhibidores de renina - Google Patents

Derivados de piperidina 3,5-sustituidos como inhibidores de renina

Info

Publication number
AR067132A1
AR067132A1 ARP080102691A ARP080102691A AR067132A1 AR 067132 A1 AR067132 A1 AR 067132A1 AR P080102691 A ARP080102691 A AR P080102691A AR P080102691 A ARP080102691 A AR P080102691A AR 067132 A1 AR067132 A1 AR 067132A1
Authority
AR
Argentina
Prior art keywords
alkoxy
alkyl
compound
treatment
class
Prior art date
Application number
ARP080102691A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39926743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067132(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR067132A1 publication Critical patent/AR067132A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Para utilizarse en el diagnostico y el tratamiento terapéutico de un animal de sangre caliente, en especial para el tratamiento de una enfermedad (= trastorno) que dependa de la actividad de la renina; al uso de un compuesto de esta clase para la preparacion de una formulacion farmacéutica para el tratamiento de una enfermedad que dependa de la actividad de la renina; al uso de un compuesto de esta clase en el tratamiento de una enfermedad que dependa de la actividad de la renina; a formulaciones farmacéuticas de un compuesto de esta clase; a un método de tratamiento, el cual comprende administrar un compuesto de esta clase, y a un método para su fabricacion. Reivindicacion 1: Un compuesto de la formula (1) en donde R1 es alquilo C1-7, el cual está opcionalmente sustituido por 1, 2 o 3 sustituyentes seleccionados a partir del grupo que consiste en hidroxilo, halogeno y alcoxilo C1-7, R2 es H, alquilo C1-7, alcoxilo C1-7, halo-alquilo C1-7, halo-alcoxilo C1-7, o alcoxilo C1-7-alcoxilo C1-7; R3 es alquilo C1-7 o cicloalquilo C3-8; R4 es H o hidroxilo; y R5 es alquilo C1-7 o cicloalquilo C3-8; o una sal del mismo, con la condicion de que se excluyan los compuestos de la formula (1), en donde R1 es metilo o isopropilo, R2 es 3-metoxi-propoxilo, R3 es ciclopropilo, R4 es H y R5 es 2-metil-propilo.
ARP080102691A 2007-06-25 2008-06-23 Derivados de piperidina 3,5-sustituidos como inhibidores de renina AR067132A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07012412 2007-06-25
EP07111290 2007-06-28

Publications (1)

Publication Number Publication Date
AR067132A1 true AR067132A1 (es) 2009-09-30

Family

ID=39926743

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102691A AR067132A1 (es) 2007-06-25 2008-06-23 Derivados de piperidina 3,5-sustituidos como inhibidores de renina

Country Status (26)

Country Link
US (2) US8383650B2 (es)
EP (2) EP2527338B1 (es)
JP (1) JP5086433B2 (es)
KR (1) KR101238479B1 (es)
CN (1) CN101687847B (es)
AR (1) AR067132A1 (es)
AU (1) AU2008267287B2 (es)
BR (1) BRPI0813900A2 (es)
CA (1) CA2689109A1 (es)
CL (1) CL2008001872A1 (es)
CO (1) CO6251267A2 (es)
CR (1) CR11153A (es)
CU (1) CU23842B1 (es)
EA (1) EA016446B1 (es)
EC (1) ECSP099825A (es)
ES (2) ES2543641T3 (es)
GT (1) GT200900324A (es)
HN (1) HN2009003463A (es)
IL (1) IL202494A0 (es)
MA (1) MA31538B1 (es)
NZ (1) NZ582098A (es)
PE (1) PE20090425A1 (es)
SG (1) SG182223A1 (es)
TN (1) TN2009000530A1 (es)
TW (1) TWI404714B (es)
WO (1) WO2009000811A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0813900A2 (pt) 2007-06-25 2014-12-30 Novartis Ag Derivados de n5-(2-etoxietil)-n3-(2-piridinil)-3,5-piperidinodicarboxa mida para uso como inibidores de renina
US20180048921A1 (en) * 2016-08-12 2018-02-15 Microsoft Technology Licensing, Llc Real-time playback diagnostics

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG44510A1 (en) 1991-12-18 1997-12-19 Schering Corp Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
IL111176A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
IL123293A (en) 1995-09-07 2003-06-24 Hoffmann La Roche Piperidine derivatives, their preparation and pharmaceutical compositions containing them
EP0862435A4 (en) 1995-11-22 1999-02-03 Merck & Co Inc Inhibitors of farnesyl-protein transferase
AU9206798A (en) 1997-08-28 1999-03-16 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
CA2333554A1 (en) 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
US6274735B1 (en) 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
EP1124822A4 (en) 1998-10-30 2002-04-03 Merck & Co Inc THROMBIN INHIBITORS
WO2000051610A1 (en) 1999-03-02 2000-09-08 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AU3386500A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
US6303593B1 (en) 1999-03-02 2001-10-16 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
WO2000063173A1 (en) 1999-04-14 2000-10-26 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
CZ20023033A3 (cs) 2000-03-17 2003-01-15 Bristol-Myers Squibb Pharma Company Deriváty cyklických beta-aminokyselin jako inhibitory matrixových metaloproteáz a TNF-alfa
FR2811673B1 (fr) 2000-07-17 2002-09-13 Rhodia Chimie Sa Utilisation de composes insatures comprenant un heterocycle comme stabilisants de polymeres halogenes
EP1326619A2 (en) 2000-10-11 2003-07-16 Merck & Co., Inc. Pyrrolidine modulators of ccr5 chemokine receptor activity
WO2002076440A2 (en) 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
US20030095958A1 (en) 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
WO2003024899A2 (en) 2001-09-17 2003-03-27 Bristol-Myers Squibb Company CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
WO2003031443A1 (en) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
MXPA04010608A (es) 2002-04-29 2004-12-13 Actelion Pharmaceuticals Ltd Derivados de 7-aril-3,9-diazabiciclo(3.3.1)non-6-eno y sus usos como inhibidores de renina en el tratamiento de enfermedades de hipertension, cardiovasculares o renales.
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
AU2003259131A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
CA2521951A1 (en) 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
CN1972912A (zh) 2003-04-29 2007-05-30 埃科特莱茵药品有限公司 新型3,4-二取代的1,2,3,6-四氢吡啶衍生物
WO2004096803A1 (en) 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd Azabicyclononene derivatives
MXPA05011497A (es) 2003-04-30 2005-12-15 Actelion Pharmaceuticals Ltd Derivados de tropano y su uso como inhibidores de la enzima de conversion de angiotensina (ace).
US20060258648A1 (en) 2003-04-30 2006-11-16 Olivier Bezencon 9-Azabicyclo'3.3.1 inon-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors
AU2004233577A1 (en) 2003-05-02 2004-11-11 Actelion Pharmaceuticals Ltd. Diazabicyclononene derivatives
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
US20080234305A1 (en) 2003-10-09 2008-09-25 Olivier Bezencon Novel Tetrahydropyridine Derivatives
RU2374228C2 (ru) 2003-11-26 2009-11-27 Новартис Аг Производные 4-фенилпиперидина в качестве ингибиторов ренина
AU2004293178B8 (en) 2003-11-26 2009-01-08 Novartis Ag Organic compounds
WO2005070877A1 (en) 2004-01-23 2005-08-04 Speedel Experimenta Ag Diamino alcohols and their use as renin inhibitors
CA2553840A1 (en) 2004-01-23 2005-08-04 Speedel Experimenta Ag Amino alcohol derivatives and their activity as renin inhibitors
WO2005070870A2 (en) 2004-01-23 2005-08-04 Speedel Experimenta Ag Amino alcohol derivatives and their use as renin inhibitors
BRPI0508961A (pt) 2004-03-19 2007-08-14 Speedel Experimenta Ag derivados de 5-amino-4-hidróxi-7-(1h-indolmetil)-8-metilnonamida como inibidores de renina para o tratamento de hipertensão
EP1725530A1 (en) 2004-03-19 2006-11-29 Speedel Experimenta AG Organic compounds
TW200613274A (en) 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
TW200631929A (en) 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
GB0428250D0 (en) 2004-12-23 2005-01-26 Novartis Ag Organic compounds
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0504850D0 (en) 2005-03-09 2005-04-13 Novartis Ag Organic compounds
EP1856032A1 (en) 2005-03-11 2007-11-21 Speedel Experimenta AG Heterocyclic-substituted alkanamides useful as renin inhibitors
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
US20090270380A1 (en) 2005-03-31 2009-10-29 Peter Herold 3,4,5-Substituted Piperidines as Renin Inhibitors
GB0508992D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
GB0510810D0 (en) 2005-05-26 2005-06-29 Novartis Ag Organic compounds
GB0511063D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
PL1948654T3 (pl) 2005-09-17 2009-12-31 Novartis Ag Pochodne 5-amino-4-hydroksy-7-(imidazo [1,2-a] pirydyn-6-ylometylo)-8-metylononyloamidu i związki pokrewne jako inhibitory reniny do leczenia nadciśnienia
CN101262864A (zh) 2005-09-17 2008-09-10 斯皮德尔实验股份公司 饱和o-杂环取代的烷酰胺
PE20071079A1 (es) * 2005-11-15 2007-12-16 Cytokinetics Inc Compuestos de piperidina como inhibidores de la proliferacion celular
EP2420491B1 (en) * 2005-12-30 2013-07-03 Novartis AG 3 , 5-substitued piperidine compounds as renin inhibitors
EP1816122A3 (en) 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
EP1979323A1 (en) 2006-01-30 2008-10-15 Speedel Experimenta AG Process for the stereoselective preparation of alcohols from alpha, beta-insaturated compounds
US20090306062A1 (en) 2006-06-08 2009-12-10 Peter Herold 2,5-Disubstituted Piperidines
GB0611697D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
GB0611696D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
TW200831463A (en) 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
EP1908471A1 (en) 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
EP1921069A1 (de) 2006-11-08 2008-05-14 Speedel Experimenta AG Verfahren zur Herstellung von 2-Alkyl-3-heterocyclyl-prop-2-en-1-olen
WO2008113835A1 (en) 2007-03-21 2008-09-25 Novartis Ag Process for preparing (r or s)-5-{1-azido-3-[6-methoxy-5-(3-methoxy-propoxy)-pyridin-3-ylmethyl]-4-methyl-pentyl}-3-alkyl-dihydro-furan-2-one
BRPI0813900A2 (pt) 2007-06-25 2014-12-30 Novartis Ag Derivados de n5-(2-etoxietil)-n3-(2-piridinil)-3,5-piperidinodicarboxa mida para uso como inibidores de renina

Also Published As

Publication number Publication date
KR20100023003A (ko) 2010-03-03
BRPI0813900A2 (pt) 2014-12-30
NZ582098A (en) 2012-03-30
TN2009000530A1 (en) 2011-03-31
US8383650B2 (en) 2013-02-26
ECSP099825A (es) 2010-01-29
TWI404714B (zh) 2013-08-11
US20080319018A1 (en) 2008-12-25
CU20090226A7 (es) 2012-02-15
US8497286B2 (en) 2013-07-30
EP2181105B1 (en) 2015-04-29
KR101238479B1 (ko) 2013-03-04
EP2527338B1 (en) 2015-05-06
EP2181105A1 (en) 2010-05-05
AU2008267287B2 (en) 2012-02-16
JP5086433B2 (ja) 2012-11-28
CU23842B1 (es) 2012-10-15
CO6251267A2 (es) 2011-02-21
WO2009000811A1 (en) 2008-12-31
HN2009003463A (es) 2012-12-10
AU2008267287A1 (en) 2008-12-31
CA2689109A1 (en) 2008-12-31
EA016446B1 (ru) 2012-05-30
CL2008001872A1 (es) 2009-02-20
ES2543641T3 (es) 2015-08-20
CR11153A (es) 2010-01-21
PE20090425A1 (es) 2009-05-12
SG182223A1 (en) 2012-07-30
GT200900324A (es) 2011-11-03
ES2541107T3 (es) 2015-07-16
TW200911782A (en) 2009-03-16
EP2527338A1 (en) 2012-11-28
EA201000037A1 (ru) 2010-06-30
IL202494A0 (en) 2010-06-30
CN101687847B (zh) 2013-11-06
MA31538B1 (fr) 2010-07-01
US20130005770A1 (en) 2013-01-03
CN101687847A (zh) 2010-03-31
JP2010531328A (ja) 2010-09-24

Similar Documents

Publication Publication Date Title
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20181519A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
ECSP088217A (es) Formas de cristal delta y épsilon de mesilato de imatinib
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
SV2016005229A (es) Inhibidores de syk
ECSP088587A (es) Compuestos de piperidina 3,5-sustituida como inhibidores de renina
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
CU20110217A7 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
EA201200318A1 (ru) Гетероциклические оксимы
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
NI201200061A (es) Derivados de quinazolina-4(3h)-ona utilizados como inhibidores de la cinasa de pi3
DOP2012000128A (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
UY31878A (es) Miméticos de glucocorticoides, métodos para su fabriciación, composiciones farmacéuticas y usos de los mismos
ECSP11011151A (es) Compuestos purina
BR112015019754A2 (pt) derivados de 2-((4-amino-3-(3-fluoro-5-hidroxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il)metil)-3-(2-(trifluoro-metil)bezil)quinazolin-4(3h)-ona e seu uso como inibidores de fosfoinositídeo 3-quinase
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CR10654A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
BRPI1016232A2 (pt) Composto de carbinol, medicamento, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doenças, e, uso do composto de carbinol
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
UY29964A1 (es) Formas de cristal f,g,h,i, y k del mesilato de imatinib
UY28896A1 (es) Formulaciones en polvo para la inhalación , las cuales contienen beta-agonistas enantioméricamente puros

Legal Events

Date Code Title Description
FA Abandonment or withdrawal